Anticoagulant and Antiplatelet Medicines: References

Kovacs RJ et al. Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol 2015;65:1340–60.

Anticoagulation. American Heart Association. http://www.heart.org/HEARTORG/Conditions/CongenitalHeartDefects/TheImpactofCongenitalHeartDefects/Anticoagulation_UCM_307110_Article.jsp. 2011. Accessed February 11, 2015.

The impact of congenital heart defects. American Heart Association. http://www.heart.org/HEARTORG/Conditions/CongenitalHeartDefects/TheImpactofCongenitalHeartDefects/The-Impact-of-Congenital-Heart-Defects_UCM_001218_Article.jsp#.V034ek0m6gx. Updated October 21, 2016. Accessed May 2016.

Husted S, de Caterina R, Andreotti F, et al. 2014. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost; 111:781.

Kearon C, Ak EA, Comerota AJ, et al. 2012. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest; 141:e419S.

Atrial fibrillation medications. American Heart Association. http://www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/Atrial-Fibrillation-Medications_UCM_423781_Article.jsp. Updated March 28, 2016. Accessed May 2016.

US Food and Drug Administration. Medication Guide: Coumadin (warfarin sodium) Tablets. http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088578.pdf. Accessed May 2016.

What are anticoagulants and antiplatelets? The American Heart Association. http://www.heart.org/idc/groups/heart-public/@wcm/@hcm/documents/downloadable/ucm_300338.pdf. 2015. Accessed May 2016.